Key result
Re-treatment with interferon alfa yielded a sustained response in 19% of relapsers and 3% of nonresponders, occurring only with augmented dose or duration of therapy.
Why the study?
Does re-treatment with interferon alfa improve sustained response in patients with chronic hepatitis C who failed initial therapy?
Cohort (n=111)
Does re-treatment with interferon alfa improve sustained response in patients with chronic hepatitis C who failed initial therapy?
Sustained response to interferon alfa re-treatment in chronic hepatitis C patients who failed initial therapy is low and only observed with increased dose or duration.
Answers are grounded in this paper and cite their sources.
Limited sustained response rates caution against routine interferon re-treatment in prior failures; leaves open whether augmented dosing improves outcomes.
Treatment of patients with chronic hepatitis C has had limited success because of relapses and nonresponse to interferon alfa therapy (currently the only established therapeutic agent). A retrospective study was done to determine the efficacy of re-treatment with interferon and the predictors of response in patients who failed to achieve sustained response after one standard course of interferon therapy (3 million units three times a week for 24 weeks). One hundred and eleven patients (47 relapsers and 64 nonresponders), mean age 45 years, were included in the study. Eighteen relapsers and 13 nonresponders received a higher dose (5 MU), and 11 relapsers and 6 nonresponders received a longer duration (48 weeks) of interferon therapy. The remaining patients received the same regimen as the first treatment. Eighty-one percent and 23% of relapsers and nonresponders, respectively, had an end-of-treatment response, and 19% and 3% of the corresponding patient groups had a sustained response to re-treatment. Two patients with breakthrough during their first treatment were the only nonresponders with sustained response after re-treatment. Sustained response was observed only in patients who received an increased dose or duration of interferon therapy. No predictor of sustained response was found. In conclusion, sustained response to re-treatment with interferon was only observed with augmentation of dose or duration of therapy in some relapsers and patients who had breakthrough. Established predictors of response to interferon in naive patients, in particular serum hepatitis C virus RNA and genotype, were not associated with sustained response to re-treatment.
No takes yet. Share an insight, caveat, or question.
Chow et al. (1998) conducted a cohort in chronic hepatitis C (n=111). Re-treatment with interferon alfa vs. Same regimen as first treatment was evaluated on Sustained response to re-treatment. Re-treatment with interferon alfa yielded a sustained response in 19% of relapsers and 3% of nonresponders, occurring only with augmented dose or duration of therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: